Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Bielack, S ^a,d   Carrle, D ^b,d   Jost, L ^c,d  

^a KLINIKUM STUTTGART   (Germany)

^b Hematology   (Germany)

^c KANTONSSPITAL   (Switzerland)

^d ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FOLINIC ACID; IFOSFAMIDE; METHOTREXATE;

ARTICLE; BONE BIOPSY; CANCER GRADING; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; FOLLOW UP; HUMAN; LABORATORY TEST; LUNG METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE; BONE TUMOR; INCIDENCE; METASTASIS; PATHOLOGY; PRACTICE GUIDELINE; TUMOR RECURRENCE;

BONE NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OSTEOSARCOMA;

EID: 45149133744     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn102     Document Type: Article

References (18)

1. Stiller CA, Craft AW, Corazziari I. Survival of children with bone sarcoma in Europe since 1978: Results from the EUROCARE study. Eur J Cancer 2001; 37: 760-766.
2. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999; 341: 342-352.
3. Fletcher CDM, Unni KK, Mertens F (eds). WHO classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press 2002.
4. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop 1980; 153: 106-120.
5. Sobin LH, Wittekind C. UICC TNM Classification of malignant tumors, 6th Edition. New York: Wiley 2002.
6. Bielack SS, Machatschek JN, Flege S, Jürgens H. Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004; 5: 1243-1256.
7. Picci P, Sangiorgi L, Rougraff BT et al. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994; 12: 2699-2705.
8. Ferrari S, Smeland S, Mercuri M et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarooma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23: 8845-8852.
9. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007; 99: 112-128.
10. Goorin AM, Schwartzentruber DJ, Devidas M et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003; 21: 1574-1580.
11. Bielack SS, Kempf-Bielack B et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790.
12. Grimer RJ, Cannon SR, Taminiau AM et al. Osteosarcoma over the age of forty. Eur J Cancer 2003; 39: 157-163.
13. Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006; 30: 445-451.
14. Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patents treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
15. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival. J Clin Oncol 2003; 21: 710-715.
16. Kempf-Bielack B, Bielack SS, Jürgens H et al. Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005; 23: 559-568.
17. Picci P, Vanel D, Briccoli A et al. Computed tomography of pulmonary metastases from osteosarcoma: The less poor technique. A study of 51 patents with histological correlation. Ann Onool 2001; 12: 1601-1604.
18. Meyers PA, Heller G, Healey J et al. Chemotherapy for nonmetastatc osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10: 5-15.